12/21
01:08 am
mist
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at
Wall
Low
Report
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at
Wall
12/17
05:38 pm
mist
Aptar's Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT) [Yahoo! Finance]
Low
Report
Aptar's Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT) [Yahoo! Finance]
12/16
10:18 am
mist
Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval [Yahoo! Finance]
Medium
Report
Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval [Yahoo! Finance]
12/16
07:19 am
mist
Milestone Pharmaceuticals (NASDAQ:MIST) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Milestone Pharmaceuticals (NASDAQ:MIST) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
12/16
05:25 am
mist
Milestone Pharmaceuticals (MIST): Taking Stock of Valuation After FDA Approval of CARDAMYST Nasal Spray [Yahoo! Finance]
Medium
Report
Milestone Pharmaceuticals (MIST): Taking Stock of Valuation After FDA Approval of CARDAMYST Nasal Spray [Yahoo! Finance]
12/15
05:47 pm
mist
Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher [Seeking Alpha]
Medium
Report
Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher [Seeking Alpha]
12/15
11:08 am
mist
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at Cowen Inc from a "hold" rating to a "buy" rating.
Medium
Report
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at Cowen Inc from a "hold" rating to a "buy" rating.
12/15
11:00 am
mist
Milestone Pharmaceuticals (NASDAQ:MIST) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Milestone Pharmaceuticals (NASDAQ:MIST) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/15
10:16 am
mist
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock.
Low
Report
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock.
12/12
08:13 pm
mist
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) [Yahoo! Finance]
Medium
Report
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) [Yahoo! Finance]
12/12
08:00 pm
mist
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Medium
Report
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
12/2
05:21 pm
mist
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/26
04:31 pm
mist
Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects [Yahoo! Finance]
Low
Report
Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects [Yahoo! Finance]
11/25
01:54 pm
mist
Milestone Pharmaceuticals (NASDAQ:MIST) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Milestone Pharmaceuticals (NASDAQ:MIST) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/23
02:11 am
mist
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at
Wall
Low
Report
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at
Wall
11/18
06:27 am
mist
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Could Be 44% Below Their Intrinsic Value Estimate [Yahoo! Finance]
Low
Report
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Could Be 44% Below Their Intrinsic Value Estimate [Yahoo! Finance]
11/12
08:21 am
mist
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update [Yahoo! Finance]
Neutral
Report
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update [Yahoo! Finance]
11/12
07:01 am
mist
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Low
Report
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
11/4
04:05 pm
mist
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/3
08:00 am
mist
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
Medium
Report
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
10/25
12:09 pm
mist
Milestone Pharmaceuticals (NASDAQ:MIST) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Milestone Pharmaceuticals (NASDAQ:MIST) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/9
08:45 am
mist
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025 [Yahoo! Finance]
Low
Report
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025 [Yahoo! Finance]
10/9
08:00 am
mist
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
Medium
Report
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
10/7
08:40 am
mist
Milestone Pharmaceuticals: Playing The Long Ball In Cardiovascular Treatment [Seeking Alpha]
Low
Report
Milestone Pharmaceuticals: Playing The Long Ball In Cardiovascular Treatment [Seeking Alpha]